Geron Stock Performance
| GERN Stock | USD 4.12 0.05 1.20% |
The company retains a Market Volatility (i.e., Beta) of 1.08, which attests to a somewhat significant risk relative to the market. Geron returns are very sensitive to returns on the market. As the market goes up or down, Geron is expected to follow. At this point, Geron has a negative expected return of -0.0667%. Please make sure to check out Geron's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Geron performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Geron has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Geron is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (1.20) | Five Day Return 0.49 | Year To Date Return 92.52 | Ten Year Return 16.06 | All Time Return (43.79) |
Last Split Factor 1058:1000 | Last Split Date 2014-07-22 |
1 | Disposition of 1600000 shares by Ziegler James of Geron at 4.41 subject to Rule 16b-3 | 09/09/2024 |
2 | Rams place Puka Nacua, two offensive linemen on injured list and sign help | 09/11/2024 |
3 | Acquisition by Ofarrell Elizabeth G. of 180000 shares of Geron at 3.88 subject to Rule 16b-3 | 09/17/2024 |
4 | Is Geron Corporation the Best NASDAQ Stock Under 5 | 10/03/2024 |
5 | Geron Receives New Coverage from Analysts at Scotiabank | 10/17/2024 |
6 | Geron Corporation Announces Up to 375 Million in Funding with Royalty Pharma and Pharmakon Advisors | 11/07/2024 |
7 | Geron Corp Q3 2024 Earnings Call Highlights Strong Rytelo Launch and Strategic ... | 11/08/2024 |
8 | Gerons SWOT analysis oncology biotech stock poised for growth | 11/12/2024 |
9 | RA Capital Managements Strategic Acquisition of Geron Corp Shares | 11/15/2024 |
10 | Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 11/21/2024 |
11 | Insider Trading | 11/22/2024 |
12 | Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference | 11/27/2024 |
| Begin Period Cash Flow | 57.2 M |
Geron |
Geron Relative Risk vs. Return Landscape
If you would invest 440.00 in Geron on September 1, 2024 and sell it today you would lose (28.00) from holding Geron or give up 6.36% of portfolio value over 90 days. Geron is currently does not generate positive expected returns and assumes 2.7613% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Geron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Geron Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Geron's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Geron, and traders can use it to determine the average amount a Geron's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0241
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GERN |
Estimated Market Risk
| 2.76 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Geron is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Geron by adding Geron to a well-diversified portfolio.
Geron Fundamentals Growth
Geron Stock prices reflect investors' perceptions of the future prospects and financial health of Geron, and Geron fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Geron Stock performance.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (1.00) % | ||||
| Current Valuation | 2.27 B | ||||
| Shares Outstanding | 604.5 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 8.62 X | ||||
| Price To Sales | 84.48 X | ||||
| Revenue | 237 K | ||||
| Gross Profit | (93.67 M) | ||||
| EBITDA | (174.78 M) | ||||
| Net Income | (184.13 M) | ||||
| Cash And Equivalents | 219.29 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 85.9 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 4.85 X | ||||
| Book Value Per Share | 0.48 X | ||||
| Cash Flow From Operations | (167.74 M) | ||||
| Earnings Per Share | (0.32) X | ||||
| Market Capitalization | 2.49 B | ||||
| Total Asset | 394.08 M | ||||
| Retained Earnings | (1.6 B) | ||||
| Working Capital | 233.28 M | ||||
| Current Asset | 115.89 M | ||||
| Current Liabilities | 6.63 M | ||||
About Geron Performance
By examining Geron's fundamental ratios, stakeholders can obtain critical insights into Geron's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Geron is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.5 K | -1.4 K | |
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.68) | (0.71) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.74) | (0.78) |
Things to note about Geron performance evaluation
Checking the ongoing alerts about Geron for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Geron help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Geron generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 237 K. Net Loss for the year was (184.13 M) with loss before overhead, payroll, taxes, and interest of (93.67 M). | |
| Geron currently holds about 219.29 M in cash with (167.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58. | |
| Geron has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference |
- Analyzing Geron's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Geron's stock is overvalued or undervalued compared to its peers.
- Examining Geron's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Geron's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Geron's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Geron's stock. These opinions can provide insight into Geron's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Revenue Per Share 0.047 | Quarterly Revenue Growth 171.384 | Return On Assets (0.30) | Return On Equity (0.69) |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.